How ParetoHealth Rx Consortium helps employers control pharmacy costs

💊 For many employers, one in four healthcare dollars is spent on pharmacy.    At ParetoHealth, we leverage our scale to help employers immediately lower pharmacy spend.    With the buying power of our community, Pareto Rx Consortium (PRxC) secures best-in-class pharmacy benefit manager (PBM) terms for our Members. This leads to lower costs for employers and reduced out-of-pocket prescription drug expenses for employees.   PRxC is led by an integrated team of in-house pharmacists, a clinical advisory board, pharmacy consultants, and analytics experts working together to deliver:     🔹 PBM contracting and audited performance guarantees  🔹 Pharmacy plan design and management  🔹 Prior authorization and large-claim review    👉 Case study: $120,000 in annual pharmacy savings  A PRxC plan participant was prescribed a high-cost brand-name drug for multiple sclerosis costing $124,000 annually. The Pareto in-house pharmacy team proactively identified a clinically effective, lower-cost generic alternative at just $3,636 per year. Working with the provider to approve the switch, the Pareto team helped the employer save $120,000 annually. When specialty drugs drive outsized costs, small changes can shift the trajectory of your entire plan. #PharmacySavings #SelfInsurance #CostContainment #ParetoHealth #BenefitsStrategy 

🧩 The PBM Profit Puzzle: Why does your “$10 copay” still make someone rich? Pharmacy Benefit Managers (PBMs) operate behind the scenes — but their influence on drug prices is massive. They’re the ones deciding which medications make it to your plan’s formulary…not based on patient care, but profit-driven contracts. 📊 The numbers tell the story: - PBMs marked up certain specialty and generic drugs by hundreds to thousands of percent. - An FTC report uncovered $7.3 billion in PBM revenue from just specialty generics (2017–2022). - They also profit through spread pricing and rebate retention, taking more than they give. 👀 It’s time to pull back the curtain on this hidden layer of healthcare. #FollowTheMoney #HealthcareReform #LegacyHealthcareSolutions #PBMs #HealthPolicy

Beyond the Prescription: #Pharmacists at the Center of Quality and Outcomes Pharmacy’s Role in Quality Measurement. https://lnkd.in/gQEjB7Tw Industry leaders showcase success stories of how pharmacists and pharmacy data have moved the needle on quality measures. From innovative care models to data-driven interventions, the spotlight is on the evolving role of pharmacists in shaping better care and measurable results. #NCPDP #PharmacyPrimaryCare #ReNueRX

85% of employers identify pharmacy costs as a top priority for the next 3 years in our 2025 Best Practices in Healthcare Survey. Explore additional data on managing healthcare costs https://ow.ly/h8Qr50Xb8M6 #GLP1 #pharmacy #HealthcareCosts

85% of employers identify pharmacy costs as a top priority for the next 3 years in our 2025 Best Practices in Healthcare Survey. Explore additional data on managing healthcare costs https://ow.ly/F2U650X9NV4 #GLP1 #pharmacy #HealthcareCosts

This may be the most important change in healthcare in 20 years. Do you know one of the biggest reasons drug prices are so high in the U.S.? 💊 PBMs. Drug manufacturers mark up prices for consumers by 40–80% so they can pay rebates to PBMs. Those rebates determine whether a drug gets on a formulary. Sometimes, plan sponsors see part or all of that rebate. Consumers never do. Now that’s changing. In response to commitments made to the White House earlier this year, several drug companies are going direct-to-consumer — bypassing PBMs altogether. If you pay cash, the total cost is often less than the PBM’s net price after rebates. ➡️ Example: • Wegovy via PBM: ~$1,000/month • Rebate: $450 • Cash price: $499 Same story for Cosentyx and others — at less than 50% of the PBM price. (Yes, Wegovy is still $200 in Europe… but one step at a time.) Forward-thinking employers can now drop PBM coverage for certain drugs and support employees by funding cash cards for direct purchase — lowering total cost and improving access. These changes are happening fast. And they could completely restructure how drugs are priced and paid for in America. What’s your reaction? Revolutionary step toward transparency — or chaos in the making? https://lnkd.in/gst3QW_E

85% of employers identify pharmacy costs as a top priority for the next 3 years in our 2025 Best Practices in Healthcare Survey. Explore additional data on managing healthcare costs https://ow.ly/YAXG50Xag5U #GLP1 #pharmacy #HealthcareCosts

85% of employers identify pharmacy costs as a top priority for the next 3 years in our 2025 Best Practices in Healthcare Survey. Explore additional data on managing healthcare costs https://ow.ly/o3Bi50Xb08U #GLP1 #pharmacy #HealthcareCosts

85% of employers identify pharmacy costs as a top priority for the next 3 years in our 2025 Best Practices in Healthcare Survey. Explore additional data on managing healthcare costs https://ow.ly/qnoQ50X9UzP #GLP1 #pharmacy #HealthcareCosts

85% of employers identify pharmacy costs as a top priority for the next 3 years in our 2025 Best Practices in Healthcare Survey. Explore additional data on managing healthcare costs https://ow.ly/qVmI50X9K28 #GLP1 #pharmacy #HealthcareCosts